European Patent Office (EPO) publication EP4230656A1 details a patent application for an anti-Trop-2 antibody, antigen-binding fragment, or mutant thereof, and its medical use. The application was published on March 11, 2026, with Shanghai Hansoh Biomedical Co., Ltd. and Jiangsu Hansoh Pharmaceutical Group Co., Ltd. listed as applicants.

This publication represents a new patent application filing and does not impose immediate regulatory obligations on companies. However, it is relevant for entities operating in the pharmaceutical and biotechnology sectors, particularly those involved in oncology research and development, as it pertains to intellectual property in the therapeutic antibody space. Companies should monitor the progress of this patent application and similar filings for competitive intelligence and potential licensing opportunities.